United Therapeutics Corporation
UTHR
$307.24
$1.850.61%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 19.72% | 22.89% | 19.85% | 33.70% | 25.07% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 19.72% | 22.89% | 19.85% | 33.70% | 25.07% |
| Cost of Revenue | 6.90% | 18.54% | 21.37% | 39.39% | 20.75% |
| Gross Profit | 21.39% | 23.46% | 19.67% | 33.04% | 25.65% |
| SG&A Expenses | 25.32% | 20.77% | 36.62% | 65.41% | -14.81% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 5.80% | 20.64% | 39.53% | 44.45% | 15.30% |
| Operating Income | 38.55% | 24.83% | 2.07% | 25.28% | 41.27% |
| Income Before Tax | 34.22% | 10.46% | 6.00% | 36.55% | 65.21% |
| Income Tax Expenses | 21.58% | -5.58% | 1.58% | 80.39% | 67.67% |
| Earnings from Continuing Operations | 38.78% | 15.51% | 7.29% | 27.27% | 64.35% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 38.78% | 15.51% | 7.29% | 27.27% | 64.35% |
| EBIT | 38.55% | 24.83% | 2.07% | 25.28% | 41.27% |
| EBITDA | 38.81% | 25.57% | 3.77% | 24.72% | 38.77% |
| EPS Basic | 45.93% | 21.46% | 13.33% | 25.38% | 60.15% |
| Normalized Basic EPS | 57.13% | 33.40% | 11.56% | 28.75% | 111.36% |
| EPS Diluted | 42.09% | 18.77% | 11.64% | 26.95% | 62.60% |
| Normalized Diluted EPS | 52.82% | 30.27% | 10.06% | 30.43% | 115.16% |
| Average Basic Shares Outstanding | -4.89% | -4.90% | -5.33% | 1.51% | 2.62% |
| Average Diluted Shares Outstanding | -2.21% | -2.62% | -4.04% | 0.20% | 0.81% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
